Armistice Capital LLC Sells 255,977 Shares of Humana Inc. $HUM

Key Points

• Armistice Capital LLC has significantly reduced its investment in Humana Inc. by 82% during the first quarter, selling 255,977 shares and now holding 56,023 shares valued at approximately $14.8 million.
• A number of institutional investors are increasing their stakes in Humana, with notable increases of over 40% from Canada Pension Plan Investment Board and Vident Advisory LLC.
• Humana's stock has faced mixed ratings from analysts, with a consensus rating of "Hold" and a price target averaging at $283.29, despite experiencing a recent stock price increase of 2%.

Armistice Capital LLC reduced its position in Humana Inc. (NYSE:HUM - Free Report) by 82.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 56,023 shares of the insurance provider's stock after selling 255,977 shares during the quarter. Armistice Capital LLC's holdings in Humana were worth $14,824,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Retirement Planning Co of New England Inc. boosted its stake in shares of Humana by 7.7% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 1,040 shares of the insurance provider's stock valued at $275,000 after purchasing an additional 74 shares during the last quarter. Quarry LP bought a new stake in shares of Humana in the 1st quarter valued at $205,000. Kingdon Capital Management L.L.C. bought a new stake in shares of Humana in the 1st quarter valued at $11,058,000. Vident Advisory LLC boosted its stake in shares of Humana by 42.2% in the 1st quarter. Vident Advisory LLC now owns 2,456 shares of the insurance provider's stock valued at $650,000 after purchasing an additional 729 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Humana by 41.4% in the 1st quarter. Canada Pension Plan Investment Board now owns 266,979 shares of the insurance provider's stock valued at $70,643,000 after purchasing an additional 78,126 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Wall Street Zen lowered shares of Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Royal Bank Of Canada upped their price objective on shares of Humana from $283.00 to $322.00 and gave the company an "outperform" rating in a research note on Thursday, August 21st. Bank of America cut their target price on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research note on Tuesday, June 17th. Morgan Stanley cut their target price on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 31st. Finally, Robert W. Baird cut their target price on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Seven research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the stock. Based on data from MarketBeat, Humana presently has a consensus rating of "Hold" and a consensus price target of $283.29.

Humana Stock Up 2.0%

Humana stock opened at $303.90 on Friday. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $382.72. The firm has a market capitalization of $36.55 billion, a price-to-earnings ratio of 23.32, a price-to-earnings-growth ratio of 1.79 and a beta of 0.44. The firm's fifty day moving average price is $254.43 and its two-hundred day moving average price is $254.58. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same period last year, the business posted $6.96 earnings per share. The firm's quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities research analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, September 26th. Humana's dividend payout ratio (DPR) is 27.17%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.